Werewolf Therapeutics (NASDAQ:HOWL) Raised to Strong-Buy at Zacks Research

Werewolf Therapeutics (NASDAQ:HOWL) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports.

HOWL has been the topic of several other reports. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

Werewolf Therapeutics Price Performance

HOWL opened at $0.92 on Monday. The firm has a market capitalization of $44.81 million, a PE ratio of -1.21 and a beta of 0.51. The business’s 50-day moving average is $0.76 and its two-hundred day moving average is $0.64. Werewolf Therapeutics has a 1 year low of $0.27 and a 1 year high of $2.13.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.00 million. As a group, sell-side analysts expect that Werewolf Therapeutics will post -0.89 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HOWL. Bank of America Corp DE acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth about $112,000. Squarepoint Ops LLC acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. Finally, BlackRock Inc. acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments.

Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins.